Living donor liver transplantation prior to multiple myeloma treatment in a patient with hepatitis B-associated hepatocellular carcinoma and liver cirrhosis: a case report.
10.4174/astr.2018.94.4.216
- Author:
Chan Woo CHO
1
;
Nuri LEE
;
Gyu Seong CHOI
;
Jong Man KIM
;
Choon Hyuck David KWON
;
Jae Won JOH
Author Information
1. Department of Surgery, Yeungnam University College of Medicine, Daegu, Korea.
- Publication Type:Case Report
- Keywords:
Living donor liver transplantation;
Multiple myeloma;
Hepatocellular carcinoma
- MeSH:
Carcinoma, Hepatocellular*;
Everolimus;
Hepatitis B, Chronic;
Hepatitis*;
Herpesvirus 4, Human;
Humans;
Liver Cirrhosis*;
Liver Transplantation*;
Liver*;
Living Donors*;
Middle Aged;
Multiple Myeloma*;
Peripheral Blood Stem Cell Transplantation;
Recurrence;
Tacrolimus
- From:Annals of Surgical Treatment and Research
2018;94(4):216-218
- CountryRepublic of Korea
- Language:English
-
Abstract:
Clinical outcomes of living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) in patients with multiple myeloma (MM) have not been established in terms of HCC recurrence and MM deterioration after LDLT. A 51-year-old man with chronic hepatitis B was diagnosed with HCC and MM. Since the patient also had decompensated liver cirrhosis (LC), he underwent LDLT prior to autologous peripheral blood stem cell transplantation (PBSCT) to prevent fulminant hepatitis due to HBV reactivation. The patient received Epstein-Barr virus prophylaxis and a triple immunosuppressive regimen of tacrolimus, everolimus, and steroid after LDLT. Autologous PBSCT was performed 7 months after LDLT. He showed a complete response to treatment of MM without post-LT complications or HCC recurrence. In conclusion, LDLT could be adapted for treatment of MM patients with combined HCC and decompensated LC because it is an effective strategy of preventing HBV reactivation and HCC recurrence after induction therapy of MM.
